Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Verrica Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -67.00 | -24.49 | -35.08 | -42.69 | -28.21 |
Depreciation/Amortization & Depletion | 0.84 | 0.83 | 0.47 | 0.23 | 0.26 |
Net Change from Assets/Liabilities | 9.86 | -1.80 | -0.54 | 1.64 | -1.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 17.72 | 6.81 | 7.56 | 10.62 | 2.27 |
Net Cash From Operating Activities | -38.58 | -18.65 | -27.58 | -30.21 | -27.41 |
Property & Equipment | -0.36 | -0.48 | -1.08 | -1.69 | -1.91 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 54.52 | 0.09 | -1.89 | 27.86 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.36 | 54.04 | -1.00 | -3.58 | 25.96 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 30.31 | 26.90 | 28.68 | 0.45 | 0.42 |
Issuance (Repayment) of Debt | 44.08 | -43.75 | 4.97 | 34.46 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.18 | -0.02 | 0.00 | 0.32 | 0.00 |
Net Cash from Financing Activities | 74.21 | -16.87 | 33.65 | 35.23 | 0.42 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 35.27 | 18.52 | 5.07 | 1.45 | -1.03 |
Cash at Beginning of Period | 34.27 | 15.75 | 10.69 | 9.24 | 10.27 |
Cash at End of Period | 69.55 | 34.27 | 15.75 | 10.69 | 9.24 |
Diluted Net EPS | -1.48 | -0.72 | -1.30 | -1.71 | -1.13 |
Fiscal Year End for Verrica Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -67.00 | -42.38 | -17.58 | -6.59 |
Depreciation/Amortization & Depletion | NA | 0.84 | 0.62 | 0.41 | 0.20 |
Net Change from Assets/Liabilities | NA | 9.86 | 4.99 | 5.27 | 0.70 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 17.72 | 12.70 | 2.64 | 1.09 |
Net Cash From Operating Activities | NA | -38.58 | -24.07 | -9.26 | -4.59 |
Property & Equipment | NA | -0.36 | -0.14 | -0.07 | -0.01 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.36 | -0.14 | -0.07 | -0.01 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 30.31 | 30.31 | 30.31 | 30.31 |
Issuance (Repayment) of Debt | NA | 44.08 | 44.11 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.18 | -0.17 | -0.11 | -0.03 |
Net Cash from Financing Activities | NA | 74.21 | 74.24 | 30.20 | 30.28 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 35.27 | 50.04 | 20.87 | 25.68 |
Cash at Beginning of Period | NA | 34.27 | 34.27 | 34.27 | 34.27 |
Cash at End of Period | NA | 69.55 | 84.31 | 55.14 | 59.95 |
Diluted Net EPS | NA | -0.55 | -0.54 | -0.24 | -0.15 |